Optogenetic Photoreceptor Precursors for Retinal Degeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for treating retinal degenerative diseases, such as cell replacement therapy and optogenetics, face challenges in restoring visual function in advanced stages of the disease, particularly in severe degeneration models where transplanted photoreceptor precursors fail to integrate and develop functional outer segments, and optogenetic approaches only rescue remaining cells without renewing degenerated structures.
Innovation Solution
Combining cell replacement therapy with optogenetics by introducing an optogenetic inhibitor, like Halorhodopsin or Jaws, into photoreceptor precursors before transplantation, which allows these cells to mimic healthy photoreceptor function and renew neural structures without requiring retinoid cycling between the retinal pigment epithelium and photoreceptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell replacement therapy is used to substitute degenerated photoreceptors, then photoreceptor loss can be addressed, but transplanted photoreceptors fail to develop functional outer segments in advanced disease stages
Solution Approach 1:
The patent applies preliminary action by introducing optogenetic tools (light-sensitive proteins) into photoreceptor precursor cells before transplantation. This pre-equipping allows the cells to immediately perform light-sensing functions upon transplantation, bypassing the need for proper outer segment development in the degenerated retinal environment. The cells are prepared in advance with the necessary functional capability to overcome the hostile recipient environment.
Solution Approach 2:
The patent substitutes the mechanical/biological development process of outer segments with an optogenetic system. Instead of relying on the complex biological process of outer segment formation and maintenance (which requires healthy RPE support), the invention uses genetically encoded light-sensitive proteins that can function independently of proper outer segment structure. This replaces the mechanical requirement for intact outer segments with a molecular optogenetic solution.
2Reliability
If optogenetic tools are introduced into inner retinal cells to restore visual function, then remaining cells can be rescued, but degenerated neural structures cannot be renewed
Solution Approach 1:
The patent merges two previously separate approaches: cell replacement therapy and optogenetics. By combining the transplantation of photoreceptor precursor cells with the introduction of optogenetic tools, the invention achieves both renewal of degenerated structures (through cell replacement) and restoration of visual function (through optogenetics). This unified approach allows transplanted cells to both replace lost photoreceptors and immediately restore light-sensing capability.
Solution Approach 2:
The patent creates a universal solution that addresses multiple problems simultaneously. The optogenetically equipped photoreceptor precursors can function in various disease stages and models, whether the issue is failure to develop outer segments or loss of visual function. The approach is versatile enough to work with different types of retinal degeneration and can be applied to various photoreceptor precursor sources.
3Reliability
If photoreceptor outer segments are to develop and maintain light sensitivity, then tight contact with retinal pigment epithelium is required, but this contact is compromised in diseased retinas
Solution Approach 1:
The patent extracts the light-sensing function from the outer segment structure and places it directly into the photoreceptor cell membrane via genetically encoded proteins. By taking out the essential function (light sensitivity) from the complex outer segment-RPE system, the invention makes the function independent of the compromised RPE contact. The optogenetic tools provide light-sensing capability that does not require the complex RPE-outer segment interface.
Solution Approach 2:
The optogenetic tools act as intermediaries that bridge the gap between light and the photoreceptor signaling pathway. Instead of relying on the natural rhodopsin-outer segment-RPE visual cycle, the introduced light-sensitive proteins directly mediate light detection and signal transduction. These intermediary proteins bypass the need for healthy RPE support and outer segment maintenance mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the restoration of visual function in blind mice by integrating photoreceptor precursors that express optogenetic inhibitors, forming synaptic connections, and transmitting signals to retinal ganglion cells, even without fully developed outer segments, thus addressing the limitations of existing treatments for advanced retinal degeneration.
Implementation Method 1
Illumination of cells expressing this optogenetic tool generateshyperpolarization, thus mimicking the function of healthy photoreceptors to light
Data Source
Figure 1
Figure 2A~2F
Figure 2G~3B
AI summary
The present invention relates to photoreceptor precursor cells comprising a heterologous nucleic acid encoding an optogenetic inhibitor. The present invention also relates to a pharmaceutical composition comprising photoreceptor precursor cells of the invention and a pharmaceutically acceptable excipient. The present invention relates to photoreceptor precursor cells or pharmaceutical composition of the invention for use in the treatment of a retinal degenerative disease, preferably a retinal degenerative disease related to a loss of function or death of photoreceptors. Finally, the present invention relates to a method for producing the photoreceptor precursor cells of the invention, comprising i) providing photoreceptor precursor cells; and ii) introducing into said precursor cells a nucleic acid encoding optogenetic inhibitor.